Journal of Clinical Oncology
Articles in this Issue
Breath-based VOC analysis leveraging canine olfaction for multi-cancer detection: Insights from a 1000-sample study.
1555 Background: Volatile organic compound (VOC) analysis is a validated approach for identifying disease-specific metabolic alterations through exhaled b...
Trends and disparities in sepsis-related mortality among patients with malignancies: A 25-year nationwide analysis.
11062 Background: Sepsis is a leading cause of mortality worldwide, with cancer patients at higher risk due to immune suppression from the disease and its...
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
3004 Background: Delta-like ligand 3 (DLL3) is highly expressed in neuroendocrine carcinomas (NEC). Obrixtamig (BI 764532)...
A phase 1, multicenter, open-label study of HSK42360, a brain-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors.
3109 Background: Limitations of approved BRAF V600E inhibitors include toxicity from paradoxical activation of RAF dimerization as well as limited brain p...
INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).
1003 Background: INAVO, a highly potent and selective PI3Kα inhibitor that also promotes mutated p110α degradation, is FDA-approved in combination with PA...
Exposure to magnetic resonance imaging (MRI) procedures in relation to increased risk of early-onset colorectal cancer.
e15676 Background: The incidence of early-onset (< 50 years of age) colorectal cancer (EOCRC) has been rising at an alarming rate in developed countrie...
Clinical outcomes of first-line osimertinib in NSCLC patients with EGFR mutations.
e20649 Background: Since osimertinib was approved for the first-line treatment of non-small cell lung cancer (NSCLC) indications in 2019, its utilization...
Patterns and barriers of second-line therapy selection in HR+/HER2- metastatic breast cancer among medical oncologists in a developing country (Georgia).
e13067 Background: Hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) represents a complex therapeutic challenge, particu...
Clinical and radiological characteristics of intermediate and high-risk cases in the Brazilian early lung cancer screening trial (BRELT3): Insights into Lung-RADS categories 3 and 4 and biopsy decision-making factors.
10540 Background: Lung cancer is the leading cause of cancer death worldwide, and low-dose computed tomography (LDCT) effectively reduces mortality throug...
Neoadjuvant immune-checkpoint blockade therapy in combination with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING).
e16304 Background: Prognoses for patients with hepatocellular carcinoma (HCC) remain suboptimal due to the high recurrence rates following curative intend...
Healthcare disparities in hepatocellular carcinoma mortality across different racial groups in the United States: A SEER-based analysis (2000–2020).
e13792 Background: Hepatocellular cancer (HCC) is the most common primary liver malignancy in the United States. The purpose of our study is to assess the...
Real-world analysis of efficacy and safety of biweekly gemcitabine and docetaxel (GEMDOC) in heavily pretreated metastatic castration-resistant prostate cancer.
e17027 Background: Metastatic castration-resistant prostate cancer (mCRPC) has poor prognosis and median overall survival (OS) of approximately 25 months....
Expanding uptake of cervical cancer screening: Feasibility and acceptability of menstrual blood-based HPV DNA testing for cervical cancer screening.
e17513 Background: Low uptake of cervical cancer screening remains a significant public health challenge. Delayed diagnosis due to low screening rates res...
Development and validation of a model to predict future breast cancer risk after ER-positive and HER2-negative breast cancer.
10524 Background: Request for bilateral mastectomy after a unilateral breast cancer (BC) diagnosis is increasing. In many cases the benefit of bilateral m...
Comparative analysis of <i>PIK3CA</i> mutation detection methods in the first-in-human phase 1/1b study of inavolisib.
e13058 Background: Mutations (mut) in the alpha catalytic subunit of PI3K (p110α, PIK3CA gene) occur in ~35-40% of patients with H...
Whole-genome and transcriptome landscape of actionable driver-negative lung adenocarcinoma.
8523 Background: Driver-negative lung adenocarcinoma (DN-LUAD) without actionable genomic alterations (AGAs) has a poor prognosis. A deeper understanding...
QUINTESSENTIAL-2: A phase 3 study comparing efficacy and safety of arlocabtagene autoleucel (arlo-cel) versus standard regimens in adult patients with relapsed or refractory multiple myeloma (RRMM) refractory to lenalidomide.
TPS7564 Background: Despite advances in MM treatment, nearly all patients (pts) will relapse, highlighting the need for ne...
Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable <i>RAS</i> and <i>BRAF</i> wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the phase III TRIPLETE study by GONO.
3512 Background: TRIPLETE (NCT03231722) is a phase III trial where unresectable RAS/BRAF wt mCRC patients (pts) were randomized 1:...
Clinical decision support system based on artificial intelligence and the patient’s subjective intention treatment model: A randomized controlled clinical trial.
10596 Background: To achieve intelligent diagnosis and treatment of tumors through the application of artificial intelligence and to meet the needs of are...
A phase 2 study of CBDCA + PEM + pembrolizumab in elderly (≥75 yrs) patients with advanced non-Sq, NSCLC.
e20616 Background: Efficacy and safety of chemo-immunotherapy in elderly (≥ 75 years) patients with advanced non-Squamous (Sq), non-small cell lung cancer...
Low-dose anti-PD-(L)1 inhibitor strategies: A systematic review.
1526 Background: Immune checkpoint inhibitors (ICIs) targeting the PD-(L)1 pathway have revolutionized cancer therapy, but their high costs significantly...
Publication and data sharing of completed NCI cooperative group trials.
11023 Background: Concerns about timely publication of NIH trial results, as well as sharing of clinical trial data, have led to important initiatives. Th...
Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 3B) of the GSK-3 inhibitor elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC): Application toward patient enrichment.
4185 Background: Elraglusib is a first-in-class inhibitor of GSK-3ß, a well-credentialed target in cancer implicated in intrinsic oncologic processes and...
Evaluation of a polygenic risk score for breast cancer in Chinese women: A three-stage case-control study of 13,715 subjects.
10553 Background: Polygenic risk score (PRS) is a valuable tool for predicting the risk of breast cancer (BC). However, limited studies have been conducte...
Donafenib plus hepatic arterial infusion chemotherapy and anti-PD-1 antibody therapies for unresectable hepatocellular carcinoma.
e16172 Background: Donafenib showed promising efficacy and safety in advanced hepatocellular carcinoma (HCC). But the efficacy of Donafenib plus hepatic a...